Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

Summary

ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia of the Alzheimer's type.

Timeline

Start

2023-07-05

Primary completion

2028-03-03

Completion

2028-03-03

Drugs

Indications